Mankind Pharma - Unlocking New Vertical Through Bharat Serum Vaccines Acquisition: Motilal Oswal

Motilal Oswal Report

Mankind Pharma Ltd. has agreed to acquire Bharat Serum Vaccines for enterprise value of Rs 136 billion, implying EV/Ebitda of 28 times/22-23 times on FY24/FY25 basis.

This acquisition not only expands Mankind’s niche portfolio, but also provides a specialty research and development tech platform, in-house complex manufacturing capabilities and strong institutional reach. 

Considering access to a high-entry barrier business, a healthy mix of domestic international segments and potential for sustainable Ebitda growth (27% Ebitda YoY growth in FY25), we believe the deal valuation is fair.

We await clarity on the deal structure in terms of debt/equity fund raise to fund the deal from the concall scheduled today at 5 pm. Having said this, considering current cash of Rs 42 billion from internal accruals, we assume debt/equity of Rs 60 billion/Rs 32 billion to complete the transaction. Free cash generated from the base business would subsequently lower debt for Mankind. Maintain Buy.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.